Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir/Velpatasvir + Ribavirin for HCV DAA Failures
NCT02822794Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Jul 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sofosbuvir + velpatasvir in hepatitis C (HCV), sponsored by Gilead Sciences. Started Jul 2016; status: completed.
02
Drugs
sofosbuvir + velpatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02822794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02822794.